Dosing to rash: A phase II trial of the first-line erlotinib for patients with advanced non-small-cell lung cancer an Eastern Cooperative Oncology Group Study (E3503).
European Journal of Cancer.
Times cited: 18
Dermatologic infections in cancer patients treated with epidermal growth factor receptor inhibitor therapy.
Journal of the National Cancer Institute.
Times cited: 112